Saturday 17 October 2026
Export CHRS’s income statement to Excel — free account
Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
1.00
0.07
−6.54%
Follow CHRS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | — | — | — | 2 | 1 | 3 | 4 | 6 |
P/E ratio |
0.00 | 0.00 | — | 14.07 | 9.39 | 0.00 | 0.00 | 0.00 | 5.11 | 0.97 |
Altman Z-Score |
(0.14) | (8.39) | — | 1.82 | 2.12 | (0.95) | (4.03) | (3.67) | (5.93) | (8.83) |
P/S ratio |
6.17 | 211.43 | — | 3.52 | 2.61 | 3.69 | 3.13 | 1.15 | 5.99 | 3.94 |
P/FCF ratio |
0.00 | 0.00 | — | 47.30 | 8.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(10.19) | (20.17) | — | (1.34) | 3.67 | (3.25) | (9.61) | (9.10) | (13.65) | (20.15) |
P/Operating CF |
(13.51) | (16.96) | — | 70.86 | 37.47 | (23.01) | (6.61) | (22.85) | 5.53 | (8.44) |
Beneish M-Score |
4.91 | — | — | — | (2.50) | (4.41) | (2.77) | (1.39) | (3.21) | (3.44) |
P/B ratio |
60.64 | 16.62 | — | 11.93 | 4.42 | 12.32 | 0.00 | 0.00 | 0.00 | 2.73 |
Price to Tangible BV |
74.32 | 18.81 | — | 12.35 | 4.47 | 12.79 | 0.00 | 0.00 | 0.00 | 11.26 |
EV/Sales |
6.04 | 200.86 | — | 3.53 | 2.33 | 4.04 | 4.47 | 2.55 | 17.89 | 4.89 |
EV/EBITDA |
0.00 | 0.00 | — | 11.33 | 6.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.55) | (2.41) | — | 44.36 | 7.18 | (35.28) | (3.92) | (3.75) | (23.09) | (1.49) |
EV/FCF |
(4.43) | (2.35) | — | 47.41 | 7.54 | (34.10) | (3.88) | (3.73) | (22.08) | (1.48) |
Quick Ratio |
2.25 | 4.47 | 2.18 | 2.78 | 4.79 | 3.27 | 2.17 | 1.14 | 0.88 | 1.36 |
Current Ratio |
2.86 | 5.12 | 2.54 | 2.98 | 5.27 | 3.64 | 2.75 | 1.43 | 1.21 | 1.47 |
Net Debt/EBITDA |
0.22 | 0.11 | (0.15) | 0.01 | (0.86) | 0.03 | (1.10) | (1.78) | (0.71) | 0.76 |
Debt/Assets |
56.17% | 62.49% | 103.64% | 43.62% | 48.00% | 60.10% | 97.96% | 75.19% | 59.07% | 14.34% |
Debt/Equity |
5.18 | 3.33 | (2.67) | 1.70 | 1.44 | 4.18 | (3.43) | (2.45) | (2.01) | 0.61 |
Asset Turnover |
0.97 | 0.01 | 0.00 | 1.40 | 0.76 | 0.43 | 0.36 | 0.46 | 0.05 | 0.12 |
Operating CF/Net income |
1.98 | 0.84 | 0.76 | 0.32 | 1.17 | 0.13 | 0.83 | 0.74 | (0.72) | (0.82) |
Capex/Depreciation |
(2.17) | (1.35) | (0.24) | (0.56) | (2.50) | (0.37) | (0.55) | (0.08) | 0.00 | 0.00 |
Interest Coverage |
(14.53) | (24.30) | (21.11) | 6.12 | 7.39 | (11.49) | (7.91) | (5.01) | (18.60) | (20.12) |
| (2,049.69%) | (954.80%) | 5,197.10% | 269.68% | 68.49% | (151.62%) | 1,470.09% | 143.81% | (17.52%) | (473.47%) | |
| (65.16%) | (139.65%) | (159.75%) | 35.34% | 21.15% | (37.75%) | (50.29%) | (42.85%) | 5.29% | 47.54% | |
ROIC |
0.00% | (2,805.20%) | 0.00% | 63.58% | 67.92% | (185.69%) | (113.10%) | (78.30%) | (1,795.44%) | 0.00% |
Return on Tangible Assets |
(109.89%) | (183.41%) | (361.98%) | 38.41% | 20.93% | (64.54%) | (116.10%) | (159.68%) | 46.60% | 248.32% |
Average Days of Receivables |
3.57 | 0.00 | — | 145.55 | 120.47 | 137.51 | 190.18 | 369.65 | 1,692.07 | 159.41 |
Research and Development Expense of Revenue |
133.84% | 10,436.31% | 0.00% | 26.45% | 30.00% | 111.19% | 94.46% | 42.54% | 348.00% | 258.20% |
Selling, General and Administrative Expense of Revenue |
27.14% | 4,582.46% | 0.00% | 38.49% | 29.23% | 51.97% | 94.05% | 74.64% | 475.51% | 238.56% |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.04 | 0.01 | 0.00 | 0.01 | 0.01 | 0.11 | 0.12 | 0.18 |
Share Based Compensation of Revenue |
14.42% | 2,146.34% | 0.00% | 9.43% | 8.02% | 15.73% | 24.04% | 16.76% | 105.35% | 40.23% |
Graham Net Nets |
0.00 | 0.03 | — | 0.03 | 0.17 | 0.02 | (0.36) | (1.17) | (1.51) | 0.06 |
Graham Number |
0.00 | 0.00 | — | 6.59 | 12.80 | 0.00 | 12.24 | 10.90 | 0.00 | 4.14 |
Earnings Yield |
(11.32%) | (47.64%) | — | 7.11% | 10.64% | (24.19%) | (44.18%) | (81.85%) | 19.57% | 102.82% |
Free Cash Flow Yield |
(22.08%) | (40.37%) | — | 2.11% | 11.84% | (3.22%) | (36.81%) | (59.47%) | (13.53%) | (83.84%) |
Revenue per Share |
4.54 | 0.03 | 0.00 | 5.11 | 6.66 | 4.33 | 2.72 | 2.73 | 0.23 | 0.36 |
Operating CF per Share |
(6.03) | (3.77) | (2.45) | 0.41 | 2.16 | (0.50) | (3.11) | (1.86) | (0.18) | (1.18) |
Capex per Share |
(0.16) | (0.09) | (0.01) | (0.03) | (0.10) | (0.02) | (0.03) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(6.18) | (3.86) | (2.46) | 0.38 | 2.06 | (0.51) | (3.13) | (1.86) | (0.18) | (1.18) |
Cash per Share |
2.98 | 2.39 | 1.11 | 2.55 | 7.58 | 5.53 | 2.47 | 1.25 | 1.10 | 1.47 |
Shareholders Equity per Share |
0.46 | 0.57 | (0.59) | 1.51 | 3.93 | 1.30 | (1.77) | (2.05) | (1.15) | 0.52 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.46 | 0.57 | (0.59) | 1.51 | 3.93 | 1.30 | (1.77) | (2.05) | (1.15) | 0.52 |
Free Cash Flow |
(259.06) | (204.86) | (160.05) | 26.53 | 146.91 | (38.72) | (243.16) | (175.17) | (20.44) | (138.51) |
Working Capital |
105.11 | 117.08 | 51.17 | 228.04 | 621.83 | 437.00 | 242.54 | 143.86 | 58.60 | 66.32 |
Capital Expenditures |
(6.51) | (4.57) | (0.79) | (1.82) | (7.23) | (1.29) | (2.04) | (0.29) | — | — |
Net Current Asset Value |
2.36 | 13.40 | (53.62) | 39.30 | 206.80 | 20.72 | (237.03) | (347.40) | (238.94) | 9.38 |
EV/EBIT |
0.00 | 0.00 | — | 11.67 | 7.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 2.94 | 0.00 | 0.01 | 0.02 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | — | 11.64 | 7.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.28 | 0.27 | 0.49 | 0.56 | 0.29 | 0.44 | 0.42 | 0.74 | 2.05 | 2.92 |
Cash ROIC |
(105.90%) | (79.06%) | (116.91%) | 5.75% | 11.98% | (4.19%) | (46.29%) | (44.05%) | (7.89%) | (51.27%) |
Accounts Receivable Turnover |
111.21 | 0.00 | — | 4.95 | 3.18 | 2.33 | 1.81 | 1.39 | 0.14 | 0.60 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.21 | 0.83 | 1.83 | 3.67 | 5.06 | 6.80 | 0.27 | 0.72 |
Inventory Turnover |
— | — | 0.03 | 2.98 | 1.39 | 1.41 | 1.83 | 3.14 | 0.26 | 3.74 |
Average Days of Payables |
0.00 | 0.00 | 1,725.60 | 555.37 | 147.30 | 102.41 | 60.03 | 80.85 | 1,190.15 | 261.98 |
Days of Inventory on Hand |
— | — | 187.18 | 209.60 | 428.63 | 238.57 | 202.03 | 143.72 | 175.95 | 83.81 |
Average Receivables |
1.71 | — | — | 71.93 | 149.52 | 140.03 | 116.49 | 185.24 | 191.43 | 70.38 |
Average Payables |
25.04 | 18.15 | 15.50 | 20.64 | 20.59 | 15.68 | 13.84 | 23.37 | 31.84 | 19.19 |
Average Inventory |
— | — | 129.33 | 5.73 | 27.02 | 40.94 | 38.22 | 50.70 | 33.41 | 3.69 |
Average Assets |
195.43 | 170.55 | 131.04 | 254.20 | 625.29 | 760.49 | 580.09 | 555.23 | 539.07 | 353.44 |
Average Common Equity |
6.21 | 24.94 | (4.03) | 33.31 | 193.09 | 189.35 | (19.85) | (165.42) | (162.71) | (35.49) |
Columns are period end dates